By contrast, WEE1 inhibitors and Mepacrine did not share resistance programs with TKIs, identifying them to work via parallel pathways and as candidate agents for clinical exploration in pan-TKI-resistant CML. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.